Skip to Content

Envarsus XR (tacrolimus) Disease Interactions

There are 7 disease interactions with Envarsus XR (tacrolimus):


Tacrolimus (Includes Envarsus XR) ↔ Diabetes Mellitus

Severe Potential Hazard, High plausibility

Applies to: Diabetes Mellitus

Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM). Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others. Reversible insulin dependence has occurred in kidney and liver transplant patients. PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients. Black and Hispanic patients are at increased risk for PTDM. Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.


  1. Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991): 3169-70
  2. Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993): 677-8
  3. Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993): 2433-4
  4. "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.
  5. Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991): 3171-2
View all 5 references

Tacrolimus (Includes Envarsus XR) ↔ Hepatic Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Liver Disease

Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes. Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine. Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration. Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.


  1. Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993): 238
  2. "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.

Tacrolimus (Includes Envarsus XR) ↔ Infections

Severe Potential Hazard, Moderate plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral, Immunodeficiency

Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease. Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes. These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML). Cases of PML have been reported in patients treated with tacrolimus. Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function. PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients. Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD. It is recommended to monitor EBV serology during tacrolimus therapy. Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.


Tacrolimus (Includes Envarsus XR) ↔ Qt Interval Prolongation

Severe Potential Hazard, Moderate plausibility

Applies to: Cardiovascular Disease, Electrolyte Abnormalities, Congestive Heart Failure

Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes. It is recommended to avoid tacrolimus in patients with congenital long QT syndrome. In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.


Tacrolimus (Includes Envarsus XR) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients. Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis. Oliguria and hematuria also have been reported. The mechanism of tacrolimus-induced renal dysfunction is not well established. Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations. Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function. Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.


  1. Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991): 2789-90
  2. McCauley J, Takaya S, Fung J, et al "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991): 1444-7
  3. "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.
  4. Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994): 170-8
  5. Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991): 3153-5
  6. Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994): 105-11
  7. Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991): 3099-100
View all 7 references

Tacrolimus (Includes Envarsus XR) ↔ Hyperkalemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyperkalemia

The use of tacrolimus has been associated with hyperkalemia. Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels. Close monitoring of potassium levels is recommended. Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.


Tacrolimus (Includes Envarsus XR) ↔ Hypertension

Moderate Potential Hazard, Moderate plausibility

Applies to: Hypertension

The use of tacrolimus has been associated with hypertension. Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure. Close monitoring of blood pressure is recommended.

Envarsus XR (tacrolimus) drug Interactions

There are 1001 drug interactions with Envarsus XR (tacrolimus)

Envarsus XR (tacrolimus) alcohol/food Interactions

There are 2 alcohol/food interactions with Envarsus XR (tacrolimus)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.